# Advesya

Source: https://onco.cc/companies/advesya/  
OnCo record `advesya` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Advesya develops treatments aimed at IL-1RAP, a protein found on leukaemia cells. Its lead treatment, a CAR-T therapy made from the patient's own immune cells, is being tested in acute myeloid leukaemia that has come back or not responded.

## Summary

Advesya is a French and Swiss clinical-stage biotech company founded in 2020, according to the company, as a spin-out from the French Blood Institute (EFS) in Besançon by Christophe Ferrand and Marina Deschamps, and seeded by Jeito in 2022. Its work targets IL-1RAP, an antigen it describes as upregulated in several cancers and autoimmune conditions. CCTx-001 is an IL-1RAP-directed autologous CAR-T therapy built from CD8 and CD4 T cells, assessed in a phase 1/2 adaptive trial in relapsed or refractory acute myeloid leukaemia (NCT06281847) with sites listed in France, Germany, Spain and Sweden. ADV-101 is a first-in-class ADC made of a humanised IgG1 anti-IL-1RAP antibody carrying a topoisomerase I inhibitor payload through a cleavable linker. Its first registered cancer trial, NCT06281847, was posted on ClinicalTrials.gov in February 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Advesya SAS
- HQ: Besançon
- Type: cell-therapy
- Website: https://advesya.com/

## Notes

- Headquarters city not stated on the website; Besançon is where the company was spun out of the French Blood Institute (EFS).
- Headquarters city not stated on the website; the company calls itself French/Swiss and the registry sponsor is Advesya SAS, so country is FR.
- IL-1RAP has no target id in the corpus, so no target is linked.
- No financing amount is stated; Jeito is named only as the 2022 seed investor.
- The website's news page returned HTTP 404 on 29 October 2026; company and science pages read the same day.

## Sources

- Official website: https://advesya.com/
- Our science: CCTx-001 and ADV-101: https://advesya.com/our-science/
- ClinicalTrials.gov: phase 1/2 trial of CCTx-001 in AML (NCT06281847): https://clinicaltrials.gov/study/NCT06281847

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- companies: [Jeito Capital](https://onco.cc/companies/jeito-capital/)

---
JSON: https://onco.cc/api/v1/entities/advesya.json